Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 8:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: INFECTIONS Clear all
Completed Not applicable Interventional

Study to Assess Duration of Indwelling Catheter After Sacrocolpopexy

NCT02189291
View directory record Official record
Conditions
Pelvic Organ Prolapse, Urinary Tract Infections, Urinary Retention
Interventions
Immediate catheter removal, Post op day 1 catheter removal
Procedure
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 85 Years · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
3
States / cities
Detroit, Michigan • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Sep 12, 2026, 8:21 AM EDT
Completed Phase 3 Interventional Results available

Safety Study of A-101 Topical Solution for the Treatment of Common Warts

NCT03812510
View directory record Official record
Conditions
Common Wart
Interventions
A-101
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
1 Year and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
46
States / cities
Mobile, Alabama • Glendale, Arizona • Fort Smith, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Sep 12, 2026, 8:21 AM EDT
Completed Phase 2 Interventional Results available

Plasma Therapy of COVID-19 in Severely Ill Patients

NCT04359810
View directory record Official record
Conditions
SARS-CoV-2 Infection
Interventions
Convalescent Plasma (anti-SARS-CoV-2 plasma), Non-convalescent Plasma (control plasma)
Biological
Lead sponsor
Max O'Donnell
Other
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 12, 2026, 8:21 AM EDT
Completed Not applicable Interventional

Adopting and Demonstrating the Adaptation of Prevention Techniques (ADAPT), Harlem United Community AIDS Center

NCT00267410
View directory record Official record
Conditions
Sexually Transmitted Diseases, HIV Infections
Interventions
Healthy Relationships
Behavioral
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years to 24 Years · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Sep 12, 2026, 8:21 AM EDT
Completed Phase 1 Interventional

Randomized, Phase I/II, Dose-Ranging, Open-Label Trial of the Anti-HIV Activity of Delavirdine Mesylate (DLV; U-90,152S)

NCT00000810
View directory record Official record
Conditions
HIV Infections
Interventions
Delavirdine mesylate, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
10
States / cities
Stanford, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 12, 2026, 8:21 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants

NCT04126213
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV MAT 60 µg, RSV MAT 120 µg, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
534 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
13
States / cities
Phoenix, Arizona • Huntington Park, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2021 · Synced Sep 12, 2026, 8:21 AM EDT
Completed Phase 1 Interventional

A Study of Didanosine Use Alone or in Combination With Zidovudine in Infants Exposed to or Infected With HIV

NCT00001049
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 3 Months
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
45
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 12, 2026, 8:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

GSK1349572 Drug Interaction Study With Efavirenz

NCT01098526
View directory record Official record
Conditions
Infections, Human Immunodeficiency Virus and Herpesviridae
Interventions
GSK1349572, Efavirenz
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2017 · Synced Sep 12, 2026, 8:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

COVID-19 Self-testing Study

NCT05701878
View directory record Official record
Conditions
COVID-19
Interventions
SMARTest mobile app for COVID-19 self-testing
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 15, 2024 · Synced Sep 12, 2026, 8:21 AM EDT
Not listed Phase 2 Interventional

Gut Microbiota Changes After Fecal Microbiota Transplantation

NCT02557685
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Fecal Microbiota Transplantation
Biological
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 22, 2015 · Synced Sep 12, 2026, 8:21 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Seek, Test, and Treat Intervention to Reduce Chlamydia Trachomatis Disparities

NCT06428643
View directory record Official record
Conditions
Chlamydia, Gonorrhea, Hiv, Syphilis
Interventions
Chlamydia, gonorrhea, syphilis, and HIV screening
Other
Lead sponsor
Tulane University
Other
Eligibility
15 Years to 26 Years
Enrollment
2,322 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 12, 2026, 8:21 AM EDT
Completed Phase 1 Interventional

Escalating Multiple-Dose Safety and Tolerance of WR 6026 Hydrochloride in HIV-Infected Subjects

NCT00000740
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Sitamaquine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
2
States / cities
Indianapolis, Indiana • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 12, 2026, 8:21 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study for a New Antiviral Drug to Treat Genital Herpes Type 2

NCT01047540
View directory record Official record
Conditions
HSV-2
Interventions
AIC316, Placebo
Drug
Lead sponsor
AiCuris Anti-infective Cures AG
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
6
States / cities
Miami, Florida • Indianapolis, Indiana • Portland, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Sep 12, 2026, 8:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Safe and Healthy Schools

NCT05105789
View directory record Official record
Conditions
Sars-CoV-2 Infection, COVID-19
Interventions
BinaxNOW Test, "Lollipop" swab
Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
4 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Sep 12, 2026, 8:21 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection

NCT04553068
View directory record Official record
Conditions
Sexually Transmitted Diseases, Gonorrhea, Chlamydia
Interventions
EVO100, Placebo
Drug
Lead sponsor
Evofem Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,892 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
98
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Sep 12, 2026, 8:21 AM EDT
Completed No phase listed Observational

Genetics of Hepatitis C Virus Infection

NCT00005657
View directory record Official record
Conditions
Hepatitis C, Liver Disease
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
2 Years and older
Enrollment
870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 12, 2026, 8:21 AM EDT
Completed Not applicable Interventional Results available

Brief Educational Video for Patients Prescribed LTBI Treatment

NCT05412212
View directory record Official record
Conditions
Latent Tuberculosis
Interventions
LTBI video intervention
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
1,894 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 12, 2026, 8:21 AM EDT
Completed Not applicable Interventional Results available

Intradialytic Drug Removal by Short-daily Hemodialysis

NCT00596167
View directory record Official record
Conditions
End Stage Renal Disease, Infection
Interventions
Intravenous antibiotics
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 24, 2016 · Synced Sep 12, 2026, 8:21 AM EDT
Completed Phase 2 Interventional Results available

Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis

NCT00029107
View directory record Official record
Conditions
Hepatitis C, Vasculitis
Interventions
Rituximab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 15, 2012 · Synced Sep 12, 2026, 8:21 AM EDT
Completed Phase 1 Interventional

Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia

NCT00054236
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, filgrastim, cyclophosphamide, fludarabine phosphate, umbilical cord blood transplantation, methylprednisolone
Biological · Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Up to 120 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 26, 2020 · Synced Sep 12, 2026, 8:21 AM EDT
Completed Phase 3 Interventional

Study of Micafungin in Patients With Invasive Candidiasis or Candidemia

NCT00105144
View directory record Official record
Conditions
Candidiasis, Candidemia
Interventions
Micafungin, Caspofungin
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
62
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2014 · Synced Sep 12, 2026, 8:21 AM EDT
Completed Phase 3 Interventional Results available

Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)

NCT02531438
View directory record Official record
Conditions
Bacterial Pneumonia, Community-Acquired Infections
Interventions
Omadacycline, Moxifloxacin
Drug
Lead sponsor
Paratek Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
774 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
12
States / cities
Birmingham, Alabama • Mobile, Alabama • Laguna Hills, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Sep 12, 2026, 8:21 AM EDT
Terminated Phase 2 Interventional Results available

Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19

NCT04479358
View directory record Official record
Conditions
COVID-19
Interventions
Tocilizumab, Standard of Care
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 12, 2026, 8:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving HIV Screening With Nurse-Based Rapid Testing/Streamlined Counseling

NCT00119548
View directory record Official record
Conditions
Health Care Quality, Access, and Evaluation, Delivery of Health Care, Immune System Diseases, HIV Infections
Interventions
Rates of HIV testing and receipt of results, Sexual risk reduction; HIV knowledge improvement
Other
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 65 Years
Enrollment
251 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Sep 12, 2026, 8:21 AM EDT